Raymond James & Associates’s BridgeBio Pharma BBIO Stock Holding History

Raymond James & Associates’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$331K	Buy	13,004 +2,188	+20%	+$57.4K	﹤0.01%	3348
2024 Q2	$274K	Buy	10,816 +1,999	+23%	+$54.7K	﹤0.01%	3425
2024 Q1	$273K	Sell	8,817 -256	-3%	-$8.71K	﹤0.01%	3424
2023 Q4	$366K	Buy	+9,073	New	+$272K	﹤0.01%	3153
2023 Q3	–	Sell	-17,291	Closed	-$297K	–	3806
2023 Q2	$297K	Buy	+17,291	New	+$260K	﹤0.01%	3263
2021 Q4	–	Sell	-16,310	Closed	-$764K	–	4141
2021 Q3	$764K	Sell	16,310 -761	-4%	-$40.8K	﹤0.01%	2756
2021 Q2	$1.04M	Sell	17,071 -19	-0.1%	-$1.08K	﹤0.01%	2564
2021 Q1	$1.05M	Sell	17,090 -640	-4%	-$41.9K	﹤0.01%	2475
2020 Q4	$1.26M	Buy	+17,730	New	+$855K	﹤0.01%	2188

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's BBIO Position: Q3 2024 in Review

Raymond James & Associates increased its BridgeBio Pharma (BBIO) stake by 20% in Q3 2024, buying an estimated $57.4K and bringing the position to 13,004 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Raymond James & Associates first reported a position in BBIO in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.26M in Q4 2020. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Raymond James & Associates held 13,004 shares of BridgeBio Pharma worth $331K as of Q3 2024.
Raymond James & Associates bought 2,188 BridgeBio Pharma shares in Q3 2024, an estimated $57.4K.
BridgeBio Pharma made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3348 holding.
Raymond James & Associates first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 9 quarters since.
Raymond James & Associates's BridgeBio Pharma position peaked at $1.26M in Q4 2020.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.